- An international R&D and manufacturing enterprise powered by biotechnology at its core and an AI-driven global cross-border technology engine. The company is a US federally registered corporation invested in by Nexteye, a publicly listed Korean company.
- Dedicated to the independent R&D of cutting-edge biotechnology products and breakthrough innovation in highly active biological raw materials, it holds multiple core processes and patented formulas, building a full-chain technological barrier from raw material development to finished product output. The IEONA series life technology BIO product line has been successfully developed, featuring three core products: GeneAKG, Myo-Inositol, and 150-year-old Mountain Ginseng Cultured Root Cell Drinks – alongside the Pulsed Current GeneAKG Anti-Aging Skincare Series.
- The group boasts three laboratories operated under a US-South Korea scientist R&D alliance, along with its own GMP-compliant manufacturing facilities: a cosmetics factory, a South Korean nail product GMP factory, and a medical injection and hyaluronic acid GMP factory.
- The Group’s venture capital division covers semiconductor inspection, medical aesthetics, biotechnology, cosmeceuticals, and daily chemicals. With over USD 1 billion in managed funds and peak daily stock trading volume of USD 250 million, its financial position remains solid.
- The Group currently holds controlling stakes in 7 internationally listed companies and investments in 54 companies, with a service network covering 40,000 retail outlets worldwide. Its partners include Samsung, LG, SK, Hyundai, BYD, and other renowned enterprises, earning it a strong market reputation.
- The Group is at the industry’s advanced level in biomedical technology: it has obtained 141 technology patents and achieved multiple significant milestones, including the industry-leading Phase III clinical approval for human medical injectable hyaluronic acid granted by the Korean government, the 2022 launch of the genetic ingredient Gene-AKG, the 2024 release of skincare products featuring microcurrent pulse patent technology, and an ongoing liver cancer targeted regulation program.
- Committed to providing global consumers and partners with scientifically grounded, quality-controlled health products as well as efficient, cost-effective AI cross-border technical services.
- In global markets, the company strictly complies with relevant regulations, focusing on the import and sales of cross-border goods (manufactured in South Korea and the US, dispatched from bonded warehouses). Adopting the standard cross-border personal-use model, products are shipped globally from South Korea via fully compliant bonded warehouses, backed by a hassle-free 7-day return policy to effectively safeguard consumer rights.
Dedicated to first-in-class innovations and advanced formula R&D in biomanufacturing, we leverage 20 years of accumulated group-wide strength in biological and medical science R&D, integrating nearly 141 patented technologies. Through clinical trials evaluating product efficacy, we strive to make impactful contributions across life science sectors—including cosmeceuticals, medical aesthetics, age-defying solutions, anti-aging, and healthspan management—to elevate human quality of life. Currently, we have established strategic partnerships with numerous research institutions at home and abroad. Holding over 50 global patented technologies, the company enjoys a stellar reputation in South Korea, ranking among the top three in the industry.
The patent certificate wall of Korea’s NEXTEYE company showcases over 50 global patented technologies; the company enjoys a prestigious reputation in the Korean industry, ranking among the top three.
On June 30, 2022, NEW&NEW, a Korean company controlled by NEXTEYE, obtained the patent certificate for “Technology for Applying Proprietary Yeast Strains to Cosmetics”. This technology is currently applied by only a few cosmetics R&D companies worldwide, such as Christian Dior of France and P&G of the US. On July 19, 2023, the company received another patent certification for “Technology for Applying Microcurrent Pulses to Cosmetics”, issued by the Korean Intellectual Property Office.
As a sister company in Korea, NEW&NEW will fully support Roadmir’s year-round cosmetics R&D and handle global market production and supply, including the world-leading microcurrent GeneAKG Aurora anti-aging series.
